Tumor chemosensitization strategies based on apoptosis manipulations

Molecular Cancer Therapeutics

Volumn 2, Issue 8, 2003, Pages 805-813

  Shabbits, Jennifer A ^a,b   Hu, Yanping ^a   Mayer, Lawrence D ^a,b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Celator Technologies Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS; DRUG RESISTANCE; GENE; GENETICS; HUMAN; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

APOPTOSIS; DRUG RESISTANCE, NEOPLASM; GENES, MDR; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 2942679885     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (91)

1. Reed, J. C. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr. Opin. Oncol., 7: 541-546, 1995.
2. LaCasse, E. C., Baird, S., Korneluk, R. G., and MacKenzie, A. E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene, 17: 3247-3259, 1998. (Pubitemid 29043977)
3. Heinrich, M., Wickel, M., Schneider-Brachert, W., Sandberg, C., Gahr, J., Schwandner, R., Weber, T., Saftig, P., Peters, C., Brunner, J., Kronke, M., and Schutze, S. Cathepsin D targeted by acid sphingomyelinase-derived ceramide. EMBO J., 18: 5252-5263, 1999. (Pubitemid 29465576)
4. Siskind, L. J., Kolesnick, R. N., and Colombini, M. Ceramide channels increase the permeability of the mitochondrial outer membrane to small proteins. J. Biol. Chem., 277: 26796-26803, 2002. (Pubitemid 34951684)
5. Lucci, A., Cho, W. I., Han, T. Y., Giuliano, A. E., Morton, D. L., and Cabot, M. C. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res., 18: 475-480, 1998. (Pubitemid 28174859)
6. Liu, Y. Y., Han, T. Y., Giuliano, A. E., and Cabot, M. C. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J. Biol. Chem., 274: 1140-1146, 1999.
7. Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coso, O. A., Gutkind, S., and Spiegel, S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature, 381: 800-803, 1996. (Pubitemid 26243122)
8. Reed, J. C. Apoptosis-based therapies. Nat. Rev. Drug Discov., 1: 111-121, 2002. (Pubitemid 41646518)
9. Klasa, R. J., Bally, M. B., Ng, R., Goldie, J. H., Gascoyne, R. D., and Wong, F. M. Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin. Cancer Res., 6: 2492-2500, 2000. (Pubitemid 30399220)
10. Jansen, B., Schlagbauer-Wadl, H., Brown, B. D., Bryan, R. N., van Elsas, A., Muller, M., Wolff, K., Eichler, H. G., and Pehamberger, H. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat. Med., 4: 232-234, 1998. (Pubitemid 28137379)
11. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997. (Pubitemid 27168548)
12. Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., and Cotter, F. E. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J. Clin. Oncol., 18: 1812-1823, 2000. (Pubitemid 30261918)
13. Rudin, C. M., Otterson, G. A., Mauer, A. M., Villalona-Calero, M. A., Tomek, R., Prange, B., George, C. M., Szeto, L., and Vokes, E. E. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann. Oncol., 13: 539-545, 2002. (Pubitemid 34461136)
14. Jansen, B., Wacheck, V., Heere-Ress, E., Schlagbauer-Wadl, H., Hoeller, C., Lucas, T., Hoermann, M., Hollenstein, U., Wolff, K., and Pehamberger, H. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet, 356: 1728-1733, 2000.
15. Guensberg, P., Wacheck, V., Lucas, T., Monia, B., Pehamberger, H., Eichler, H. G., and Jansen, B. Bcl-xL antisense oligonucleotides chemosensitize human glioblastoma cells. Chemotherapy, 48: 189-195, 2002.
16. Broome, H. E., Yu, A. L., Diccianni, M., Camitta, B. M., Monia, B. P., and Dean, N. M. Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs. Leuk. Res., 26: 311-316, 2002. (Pubitemid 34037028)
17. Jiang, Z., Zheng, X., and Rich, K. M. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J. Neurochem., 84: 273-281, 2003. (Pubitemid 36182269)
18. Zaffaroni, N., and Daidone, M. G. Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. Drug Resist. Updat., 5: 65-72, 2002. (Pubitemid 35033448)
19. Zhou, M., Gu, L., Li, F., Zhu, Y., Woods, W. G., and Findley, H. W. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J. Pharmacol. Exp. Ther., 303: 124-131, 2002.
20. Kanwar, J. R., Shen, W. P., Kanwar, R. K., Berg, R. W., and Krissansen, G. W. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J. Natl. Cancer Inst. (Bethesda), 93: 1541-1552, 2001. (Pubitemid 32998483)
21. Sasaki, H., Sheng, Y., Kotsuji, F., and Tsang, B. K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res., 60: 5659-5666, 2000.
22. Bilim, V., Kasahara, T., Hara, N., Takahashi, K., and Tomita, Y. Role of XIAP in the malignant phenotype of transitional cell cancer (TCC) and therapeutic activity of XIAP antisense oligonucleotides against multidrug-resistant TCC in vitro. Int. J. Cancer, 103: 29-37, 2003. (Pubitemid 35424202)
23. Hu, Y. P., Cherton-Horvat, G., Dragowska, V., Baird, S., Korneluk, R. G., Durkin, J. P., Mayer, L. D., and LaCasse, E. C. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance therapeutic activity against human lung cancer cells when combined with anticancer drug in vitro and in vivo. Clin. Cancer Res., 9: 2826-2836, 2003. (Pubitemid 36842129)
24. Liu, Y. Y., Han, T. Y., Giuliano, A. E., Hansen, N., and Cabot, M. C. Uncoupling ceramide glycosylation by transfection of glucosylceramide synthase antisense reverses adriamycin resistance. J. Biol. Chem., 275: 7138-7143, 2000. (Pubitemid 30146262)
25. Sietsma, H., Veldman, R. J., Kolk, D., Ausema, B., Nijhof, W., Kamps, W., Vellenga, E., and Kok, J. W. 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin. Cancer Res., 6: 942-948, 2000. (Pubitemid 30159352)
26. Shabbits, J. A., and Mayer, L. D. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol. Cancer Ther., 1: 205-213, 2002.
27. Litvak, D. A., Bilchik, A. J., and Cabot, M. C. Modulators of ceramide metabolism sensitize colorectal cancer cells to chemotherapy. A novel treatment strategy. J. Gastrointest. Surg., 7: 140-148, 2003. (Pubitemid 36875811)
28. Strelow, A., Bernardo, K., Adam-Klages, S., Linke, T., Sandhoff, K., Kronke, M., and Adam, D. Overexpression of acid ceramidase protects from tumor necrosis factor-induced cell death. J. Exp. Med., 192: 601-612, 2000.
29. Selzner, M., Bielawska, A., Morse, M. A., Rudiger, H. A., Sindram, D., Hannun, Y. A., and Clavien, P. A. Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res., 61: 1233-1240, 2001. (Pubitemid 32174448)
30. Nava, V. E., Cuvillier, O., Edsall, L. C., Kimura, K., Milstien, S., Gelmann, E. P., and Spiegel, S. Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res., 60: 4468-4474, 2000. (Pubitemid 32103627)
31. Edsall, L. C., Van Brocklyn, J. R., Cuvillier, O., Kleuser, B., and Spiegel, S. N. N-Dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry, 37: 12892-12898, 1998. (Pubitemid 28433522)
32. Shirahama, T., Sweeney, E. A., Sakakura, C., Singhal, A. K., Nishiyama, K., Akiyama, S., Hakomori, S., and Igarashi, Y. In vitro and in vivo induction of apoptosis by sphingosine and N. N- dimethylsphingosine in human epidermoid carcinoma KB-3-1 and its multidrug-resistant cells. Clin. Cancer Res., 3: 257-264, 1997. (Pubitemid 27107303)
33. Endo, K., Igarashi, Y., Nisar, M., Zhou, Q. H., and Hakomori, S. Cell membrane signaling as target in cancer therapy: inhibitory effect of N. N-dimethyl and N, N, N-trimethyl sphingosine derivatives on in vitro and in vivo growth of human tumor cells in nude mice. Cancer Res., 51: 1613-1618, 1991.
34. Sachs, C. W., Safa, A. R., Harrison, S. D., and Fine, R. L. Partial inhibition of multidrug resistance by safingol is independent of modulation of P-glycoprotein substrate activities and correlated with inhibition of protein kinase C. J. Biol. Chem., 270: 26639-26648, 1995.
35. Schwartz, G. K., Haimovitz-Friedman, A., Dhupar, S. K., Ehleiter, D., Maslak, P., Lai, L., Loganzo, F., Jr., Kelsen, D. P., Fuks, Z., and Albino, A. P. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells. J. Natl. Cancer Inst. (Bethesda), 87: 1394-1399, 1995.
36. Kedderis, L. B., Bozigian, H. P., Kleeman, J. M., Hall, R. L., Palmer, T. E., Harrison, S. D., Jr., and Susick, R. L., Jr. Toxicity of the protein kinase C inhibitor safingol administered alone and in combination with chemotherapeutic agents. Fundam. Appl. Toxicol., 25: 201-217, 1995.
37. Schwartz, G. K., Ward, D., Saltz, L., Casper, E. S., Spiess, T., Mullen, E., Woodworth, J., Venuti, R., Zervos, P., Storniolo, A. M., and Kelsen, D. P. A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin. Cancer Res., 3: 537-543, 1997. (Pubitemid 27211830)
38. Ulukaya, E., and Wood, E. J. Fenretinide and its relation to cancer. Cancer Treat. Rev., 25: 229-235, 1999. (Pubitemid 29417680)
39. Maurer, B. J., Melton, L., Billups, C., Cabot, M. C., and Reynolds, C. P. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl) retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst. (Bethesda), 92: 1897-1909, 2000. (Pubitemid 32036920)
40. Coradini, D., Biffi, A., Pellizzaro, C., Pirronello, E., and Di Fronzo, G. Combined effect of tamoxifen or interferon-beta and 4- hydroxyphenyl- retinamide on the growth of breast cancer cell lines. Tumor Biol., 18: 22-29, 1997. (Pubitemid 26423281)
41. Batra, S., Maurer, B. J., and Reynolds, C. P. Fenretinide cytotoxicity in Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) cell lines is blunted by hypoxia but synergistically enhanced by safingol. San Francisco: American Association of Cancer Research, 2002.
42. Formelli, F., and Cleris, L. Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. Cancer Res., 53: 5374-5376, 1993. (Pubitemid 23342152)
43. Cobleigh, M. A., Dowlatshahi, K., Deutsch, T. A., Mehta, R. G., Moon, R. C., Minn, F., Benson, A. B., III, Rademaker, A. W., Ashenhurst, J. B., Wade, J. L., III, et al. Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer. J. Clin. Oncol., 11: 474-477, 1993. (Pubitemid 23071044)
44. Torrisi, R., and Decensi, A. Fenretinide and cancer prevention. Curr. Oncol. Rep., 2: 263-270, 2000.
45. Modrak, D. E., Lew, W., Goldenberg, D. M., and Blumenthal, R. Sphingomyelin potentiates chemotherapy of human cancer xenografts. Biochem. Biophys. Res. Commun., 268: 603-606, 2000. (Pubitemid 30119668)
46. Modrak, D. E., Rodriguez, M. D., Goldenberg, D. M., Lew, W., and Blumenthal, R. D. Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. Int. J. Oncol., 20: 379-384, 2002.
47. Arthur, G., and Bittman, R. The inhibition of cell signaling pathways by antitumor ether lipids. Biochim. Biophys. Acta, 1390: 85-102, 1998. (Pubitemid 28122329)
48. Gajate, C., Fonteriz, R. I., Cabaner, C., Alvarez-Noves, G., Alvarez-Rodriguez, Y., Modolell, M., and Mollinedo, F. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int. J. Cancer, 85: 674-682, 2000. (Pubitemid 30080481)
49. Berkovic, D. Cytotoxic etherphospholipid analogues. Gen. Pharmacol., 31: 511-517, 1998. (Pubitemid 28458917)
50. Principe, P., and Braquet, P. Advances in either phospholipids treatment of cancer. Crit. Rev. Oncol.-Hematol., 18: 155-178, 1995.
51. Ruiter, G. A., Verheij, M., Zerp, S. F., and van Blitterswijk, W. J. Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int. J. Radiat. Oncol. Biol. Phys., 49: 415- 419, 2001.
52. Runge, M. H., Andreesen, R., Pfleiderer, A., and Munder, P. G. Destruction of human solid tumors by alkyl lysophospholipids. J. Natl. Cancer Inst. (Bethesda), 64: 1301-1306, 1980. (Pubitemid 10109721)
53. Herrmann, D. B., Pahlke, W., Opitz, H. G., and Bicker, U. In vivo antitumor activity of ilmofosine. Cancer Treat. Rev., 17: 247-252, 1990.
54. Unger, C., Peukert, M., Sindermann, H., Hilgard, P., Nagel, G., and Eibl, H. Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. Cancer Treat. Rev., 17: 243-246, 1990.
55. Dummer, R., Roger, J., Vogt, T., Becker, J., Hefner, H., Sindermann, H., and Burg, G. Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas. Prog. Exp. Tumor Res., 34: 160-169, 1992.
56. Vogler, W. R. Bone marrow purging in acute leukemia with alkyl-lysophospholipids: a new family of anticancer drugs. Leuk. Lymphoma, 13: 53-60, 1994. (Pubitemid 24122127)
57. Ahmad, I., Filep, J. J., Franklin, J. C., Janoff, A. S., Masters, G. R., Pattassery, J., Peters, A., Schupsky, J. J., Zha, Y., and Mayhew, E. Enhanced therapeutic effects of liposome-associated 1-O-octadecyl-2-O-methyl-sn-glycero- 3-phosphocholine. Cancer Res., 57: 1915-1921, 1997. (Pubitemid 27209721)
58. Hong, T., Ortel, T., Truax, R., Walker, C., Bach, K., Swenson, C., Welles, L., and Hurwitz, H. A phase I pharmacokinetic (pk) dose-escalating trial of TLC ELL-12 in patients (pts) with refractory solid tumors. Orlando, FL: American Society of Clinical Oncology, 2002.
59. Arellano, M., and Moreno, S. Regulation of CDK/cyclin complexes during the cell cycle. Int. J. Biochem. Cell Biol., 29: 559-573, 1997. (Pubitemid 27243984)
60. Sedlacek, H. H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol.-Hematol., 38: 139-170, 2001. (Pubitemid 32328317)
61. Kitada, S., Zapata, J. M., Andreeff, M., and Reed, J. C. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down- regulate anti-apoptosis proteins in B-cell chronic lymphocytic leukemia. Blood, 96: 393-397, 2000. (Pubitemid 30463354)
62. Senderowicz, A. M., and Sausville, E. A. Preclinical and clinical development of cyclin-dependent kinase modulators. J. Natl. Cancer Inst. (Bethesda), 92: 376-387, 2000. (Pubitemid 30154819)
63. Monks, A., Harris, E. D., Vaigro-Wolff, A., Hose, C. D., Connelly, J. W., and Sausville, E. A. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines. Investig. New Drugs, 18: 95-107, 2000. (Pubitemid 30261284)
64. Abe, S., Kubota, T., Otani, Y., Furukawa, T., Watanabe, M., Kumai, K., Akiyama, T., Akinaga, S., and Kitajima, M. UCN-01 (7-hydoxystaurosporine) inhibits in vivo growth of human cancer cells through selective perturbation of G1 phase checkpoint machinery. Jpn. J. Cancer Res., 92: 537-545, 2001. (Pubitemid 32515095)
65. Senderowicz, A. M., Headlee, D., Lush, R., Arbuck, S., Bauer, K., Figg, W. D., Murgo, A., Inoue, K., Kobashi, S., Kuwabara, T., and Sausville, E. A. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms. Atlanta, GA: American Society of Clinical Oncology, 1999.
66. Bible, K. C., and Kaufmann, S. H. Cytotoxic synergy between flavopiridol (NSC 649890. L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res., 57: 3375-3380, 1997. (Pubitemid 27355478)
67. Motwani, M., Jung, C., Sirotnak, F. M., She, Y., Shah, M. A., Gonen, M., and Schwartz, G. K. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin. Cancer Res., 7: 4209-4219, 2001. (Pubitemid 34044647)
68. Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Jr., Koss, W., Morgan, C. D., Stinson, S. F., Siford, T. J., Alvord, W. G., Klabansky, R. L., and Sausville, E. A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood, 91: 2482-2490, 1998. (Pubitemid 28155524)
69. Thomas, J. P., Tutsch, K. D., Cleary, J. F., Bailey, H. H., Arzoomanian, R., Alberti, D., Simon, K., Feierabend, C., Binger, K., Marnocha, R., Dresen, A., and Wilding, G. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother. Pharmacol., 50: 465-472, 2002. (Pubitemid 35435525)
70. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., and Sausville, E. A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol., 16: 2986-2999, 1998. (Pubitemid 28417418)
71. Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., and Vokes, E. E. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J. Clin. Oncol., 18: 371-375, 2000. (Pubitemid 30056427)
72. Schwartz, G. K., Ilson, D., Saltz, L., O'Reilly, E., Tong, W., Maslak, P., Werner, J., Perkins, P., Stoltz, M., and Kelsen, D. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol., 19: 1985-1992, 2001. (Pubitemid 32702543)
73. Bennett, P., Mani, S., O'Reilly, S., Wright, J., Schilsky, R. L., Vokes, E. E., and Grochow, L. Phase II trial of flavopiridol in metastatic colorectal cancer: preliminary results. Atlanta, GA: American Society of Clinical Oncology, 1999.
74. Tan, A. R., and Swain, S. M. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy. Semin. Oncol., 29: 77-85, 2002. (Pubitemid 34816069)
75. Zhai, S., Senderowicz, A. M., Sausville, E. A., and Figg, W. D. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann. Pharmacother., 36: 905-911, 2002. (Pubitemid 34517422)
76. Bos, J. L. ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989. (Pubitemid 19213607)
77. Vojtek, A. B., Hollenberg, S. M., and Cooper, J. A. Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell, 74: 205-214, 1993. (Pubitemid 23219891)
78. Rowinsky, E. K., Windle, J. J., and Von Hoff, D. D. Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J. Clin. Oncol., 17: 3631-3652, 1999. (Pubitemid 29517936)
79. Sebti, S. M., and Hamilton, A. D. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther., 74: 103-114, 1997. (Pubitemid 27337356)
80. Wang, E., Casciano, C. N., Clement, R. P., and Johnson, W. W. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein. Cancer Res., 61: 7525-7529, 2001. (Pubitemid 32995043)
81. Ryan, D., Eder, J., Supko, J., Lynch, T., Amrein, P., Fuchs, C., Roper, K., Washington, T., Sonnichsen, D., Tuck, D., and Clark, J. Phase I clinical trial of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors. New Orleans, LA: American Society of Clinical Oncology, 2000.
82. Tabernero, J., Sonnichsen, D., Albanell, J., Damle, B., Rojo, F., Christopher, L., Marimon, I., Dendler, R., Trigo, J. M., Manne, S., Garcia, M., Montoro, J. B., and Baselga, J. A phase I pharmacokinetic (PK) and serial tumor and PBMC pharmacodynamic (PD) study of weekly BMS-214662, a farnesyltransferase (FT) inhibitor, in patients with advanced solid tumors. San Francisco: American Society of Clinical Oncology, 2001.
83. Bailey, H. H., Marnocha, R., Arzoomanian, R., Alberti, R., Binger, K., Volkman, J., Feierabend, C., Ellingen, S., Black, S., Hampton, K., Cooper, M., Hott, T., and Wilding, G. Phase I trial of weekly paclitaxel and BMS214662 in patients with advanced solid tumors. American Society of Clinical Oncology, 2001.
84. Adjei, A. A., Erlichman, C., Davis, J. N., Cutler, D. L., Sloan, J. A., Marks, R. S., Hanson, L. J., Svingen, P. A., Atherton, P., Bishop, W. R., Kirschmeier, P., and Kaufmann, S. H. A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res., 60: 1871-1877, 2000. (Pubitemid 30207646)
85. Hurwitz, H., Amado, R., Prager, D., Hecht, J., Cohen, D., Conway, D., Kadib, L., Mayers, A., Calzetta, A., Statkevich, P., Cutler, D., and Rosen, L. Phase I pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancers. New Orleans, LA: American Society of Clinical Oncology, 2000.
86. Khuri, F., Glisson, B., Meyers, M., Herbst, R., Thall, P., Munden, R., Bangert, S., Cascino, M., Blumenschein, G., Pisters, K., and Hong, W. Phase I study of farnesyl transferase inhibitor (FTI) SCH66336 with paclitaxel in solid tumors: dose finding, pharmacokinetics, efficacy/safety. New Orleans, LA: American Society of Clinical Oncology, 2000.
87. Sharma, S., Kemeny, N., Kelsen, D. P., Ilson, D., O'Reilly, E., Zaknoen, S., Baum, C., Statkevich, P., Hollywood, E., Zhu, Y., and Saltz, L. B. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol., 13: 1067-1071, 2002.
88. Lancet, J. E., Rosenblatt, J. D., and Karp, J. E. Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias. Semin. Hematol., 39: 31-35, 2002. (Pubitemid 34988413)
89. Peeters, M., Va, C. E., Marse, H., Palmer, P., Walraven, V., and Willems, L. Phase-I combination trial of the farnesyltransferase inhibitor (FTI) R115777 with a 5FU/LV regimen in advanced colorectal (CRC) or pancreatic (PC) cancer. Atlanta, GA: American Society of Clinical Oncology, 1999.
90. Karp, J. E., Kaufmann, S. H., Adjei, A. A., Lancet, J. E., Wright, J. J., and End, D. W. Current status of clinical trials of farnesyltransferase inhibitors. Curr. Opin. Oncol., 13: 470-476, 2001. (Pubitemid 33027899)
91. Piccart-Gebhart, M. J., Branle, F., de Valeriola, D., Dubuisson, M., Hennebert, P., Gil, T., Forget, F., Seifert, W. F., Thibault, A., Bol, C. J., and Awada, A. Phase I, clinical and pharmacokinetic (PK) trial of the farnesyl transferase inhibitor (FTI) R115777 + docetaxel: a promising combination in patients (PTS) with solid tumors. San Francisco: American Society of Clinical Oncology, 2001.